Chugai Pharmaceutical Co (STU:CUP) Asset Impairment Charge : €0 Mil (TTM As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Chugai Pharmaceutical Co Asset Impairment Charge?

Chugai Pharmaceutical Co's Asset Impairment Charge for the three months ended in Jun. 2024 was €0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was €0 Mil.

Chugai Pharmaceutical Co Asset Impairment Charge Historical Data

The historical data trend for Chugai Pharmaceutical Co's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Asset Impairment Charge Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Chugai Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Chugai Pharmaceutical Co Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Chugai Pharmaceutical Co Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (STU:CUP) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

CHGCY:USA CHGCF:USA 4519:Japan

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.

Chugai Pharmaceutical Co Headlines

No Headlines